News Search Results
Sep 08, 2025, 09:00 ET Matica Biotechnology and Cirsium Biosciences Announce AAV Manufacturing Collaboration
2025 /PRNewswire/ -- Matica Biotechnology, Inc. (Matica Bio), a leading contract development and manufacturing organization (CDMO) specializing in viral vector production, and Cirsium Biosciences ("Cirsium"), a biotechnology company developing a breakthrough plant-based
More news about: Matica Biotechnology, Inc.
Sep 08, 2025, 09:00 ET Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Clinical Programs in Heart Failure and Atrial Fibrillation and Presents Results of SGK1 Inhibition Combined with Jardiance (empagliflozin), an SGLT2 inhibitor, in a Pressure Overload Heart Failure Model at ESC Congress 2025
MONTREAL, Sept. 8, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced the presentation
More news about: Thryv Therapeutics Inc.
Sep 08, 2025, 09:00 ET BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
Patient Information. About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
Sep 08, 2025, 08:30 ET From Bench to Batch: Potency Assays and the Importance of Antibodies, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 08, 2025, 08:30 ET CGT Oncology Trials: IRB/IBC Strategies, Trends and Operational Insights, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 08, 2025, 08:30 ET Successfully Moving from On-Premises QMS to SaaS eQMS, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 08, 2025, 08:30 ET Xtalks Named Media Partner for KP Morgan's 9th Operational Excellence in Clinical Trials Summit in Toronto
Kovacevic, Editor-in-Chief of Xtalks. The two-day summit will convene executives, directors, managers and leaders from pharmaceutical companies, biotechnology firms, medical device organizations, CROs, academic institutions, patient advocacy groups and more. "At KP-Morgan Group, we are delighted
More news about: Xtalks
Sep 08, 2025, 08:15 ET ETHZilla Announces ETH Accumulation and Leadership Updates
DeFi founders, infrastructure pioneers and other ecosystem heavyweights. The Company, originally formed as an innovative biotechnology company, has also been evolving its business towards software enabled gaming and entertainment. In addition to its ETH treasury strategy
More news about: ETHZilla Corporation
Sep 08, 2025, 08:00 ET INTRODUCING DAMASTÍQUE: A LATINA-FOUNDED, SUN-FIRST SKINCARE BRAND REDEFINING SKIN HEALTH AND PREVENTION
Aissa Duffy, Damastíque stands apart by pairing 20% zinc oxide mineral protection with its proprietary Antioxid Melanocyte Calm™ complex, a biotechnology-powered blend that helps deliver thoughtful, effective, and ethically sourced solutions for pigmentation-prone, sensitive, and hormonally shifting
More news about: Damastíque
Sep 08, 2025, 08:00 ET Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced it has completed dosing of the fourth cohort in its ongoing Phase 1 clinical
More news about: Anixa Biosciences, Inc.
Sep 08, 2025, 08:00 ET Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar
Sept. 8, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseases, announces CEO and Chairman Dr. Joseph Sinkule
More news about: Klotho Neurosciences, Inc.
Sep 08, 2025, 08:00 ET Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar
Sept. 8, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseases, announces CEO and Chairman Dr. Joseph Sinkule
More news about: Klotho Neurosciences, Inc.
Sep 08, 2025, 07:00 ET Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
Sept. 8, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Sep 08, 2025, 07:00 ET Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions
References: 1. Bennouna J. Lancet Oncol (14):29-37, 2013 About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated promising results
More news about: Oncolytics Biotech® Inc.
Sep 08, 2025, 06:55 ET Centrifuge Market worth $0.63 billion by 2030 - Exclusive Report by MarketsandMarkets™
centrifuge market is the increasing demand for efficient separation and purification processes across diverse industries, particularly pharmaceuticals, biotechnology, food and beverage, chemicals, and wastewater treatment. In pharmaceuticals and biotech, centrifuges are essential for applications such as cell
More news about: MarketsandMarkets
Sep 08, 2025, 06:45 ET Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Sep 08, 2025, 06:35 ET Transcatheter Aortic Valve Replacement (TAVR) Market to Reach USD 14.06 Billion by 2035, with CAGR 6.9% Driven by Aging and Minimally Invasive Heart Procedures - Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Sep 08, 2025, 03:41 ET Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
KER-0193 was discovered and developed by Kaerus Bioscience, a UK headquartered biotechnology company co-founded by Medicxi in 2016. Kaerus Bioscience successfully completed a Phase 1 clinical study of KER-0193 in healthy volunteers in
More news about: Servier
Sep 08, 2025, 03:39 ET Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
KER-0193 was discovered and developed by Kaerus Bioscience, a UK headquartered biotechnology company co-founded by Medicxi in 2016. Kaerus Bioscience successfully completed a Phase 1 clinical study of KER-0193 in healthy volunteers in
More news about: Servier
Sep 08, 2025, 00:15 ET Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines
it has entered into a strategic investment agreement with Bloomage Biotech (stock code: 688363.SH) through its wholly-owned subsidiary, Bloomage Biotechnology (Hong Kong) Limited. Under the terms of the agreement, Bloomage Biotech has subscribed for shares in Sirnaomics'
More news about: Sirnaomics
Sep 07, 2025, 22:00 ET Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines
As a pioneering biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, Epigenic has
More news about: Epigenic Therapeutics
Sep 06, 2025, 11:05 ET BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
Prescribing Information, including Boxed Warning. About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
Sep 06, 2025, 10:15 ET Antibody Discovery Market worth US$3.54 billion by 2030 with 13.3% CAGR | MarketsandMarkets™
the demand for antibodies with improved efficacy, safety, and manufacturability profiles suitable for clinical development. Pharmaceutical and biotechnology companies frequently utilize engineering and optimization services to refine initial antibody leads generated through screening platforms, ensuring
More news about: MarketsandMarkets
Sep 05, 2025, 22:49 ET UNCY Investors: If you Lost Significant Money in UNCY Contact Robbins LLP for Information About the Securities Fraud Class Action Against Unicycive Therapeutics, Inc.
securities between March 29, 2024 and June 27, 2025. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies to address unmet medical needs in the U.S.
More news about: Robbins LLP
Sep 05, 2025, 17:00 ET BIOVAXYS ANNOUNCES SHARE CONSOLIDATION
receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.